| Characteristic . | Total With PASC, No. (%) . | aOR . | 95% CI . | P Value . |
|---|---|---|---|---|
| Age, per 10 y | 1.17 | 1.14–1.19 | <.001 | |
| 0–17 | 110 (1.6) | |||
| 18–39 | 730 (5.2) | |||
| 40–64 | 984 (7.4) | |||
| ≥65 | 1033 (15.0) | |||
| Sex | ||||
| Male | 1100 (6.0) | … | … | |
| Female | 1757 (7.7) | 1.51 | 1.38–1.64 | <.001 |
| Race | ||||
| White | 2639 (7.1) | … | … | |
| Asian | 67 (5.4) | 1.07 | .81–1.39 | .6 |
| Black | 99 (6.0) | 1.07 | .85–1.33 | .5 |
| Other | 52 (5.5) | 1.01 | .74–1.36 | >.9 |
| COVID-19 variant era | ||||
| Ancestral | 351 (8.1) | … | … | |
| Alpha | 78 (7.4) | 0.90 | .67–1.18 | .5 |
| Delta | 1179 (7.2) | 0.97 | .84–1.12 | .7 |
| Omicron | 1249 (6.5) | 0.67 | .58–.78 | <.001 |
| Hospitalization for COVID-19 | ||||
| No | 1567 (4.1) | … | … | |
| Hospitalized, no ICU | 909 (37.4) | 10.1 | 9.06–11.2 | <.001 |
| Hospitalized, ICU | 381 (40.3) | 11.0 | 9.43–12.8 | <.001 |
| CCI, severity weighted, per increase of 1 | 1.05 | 1.03–1.07 | <.001 | |
| 0 | 1337 (4.5) | |||
| ≥1 | 1520 (13.6) | |||
| Vaccination status at time of SARS-CoV-2 infection | ||||
| Unvaccinated | 1654 (6.9) | … | … | |
| 2 mRNA doses | 584 (6.1) | 0.98 | .87–1.09 | .7 |
| >2 mRNA doses | 619 (8.2) | 1.10 | .97–1.24 | .14 |
| Characteristic . | Total With PASC, No. (%) . | aOR . | 95% CI . | P Value . |
|---|---|---|---|---|
| Age, per 10 y | 1.17 | 1.14–1.19 | <.001 | |
| 0–17 | 110 (1.6) | |||
| 18–39 | 730 (5.2) | |||
| 40–64 | 984 (7.4) | |||
| ≥65 | 1033 (15.0) | |||
| Sex | ||||
| Male | 1100 (6.0) | … | … | |
| Female | 1757 (7.7) | 1.51 | 1.38–1.64 | <.001 |
| Race | ||||
| White | 2639 (7.1) | … | … | |
| Asian | 67 (5.4) | 1.07 | .81–1.39 | .6 |
| Black | 99 (6.0) | 1.07 | .85–1.33 | .5 |
| Other | 52 (5.5) | 1.01 | .74–1.36 | >.9 |
| COVID-19 variant era | ||||
| Ancestral | 351 (8.1) | … | … | |
| Alpha | 78 (7.4) | 0.90 | .67–1.18 | .5 |
| Delta | 1179 (7.2) | 0.97 | .84–1.12 | .7 |
| Omicron | 1249 (6.5) | 0.67 | .58–.78 | <.001 |
| Hospitalization for COVID-19 | ||||
| No | 1567 (4.1) | … | … | |
| Hospitalized, no ICU | 909 (37.4) | 10.1 | 9.06–11.2 | <.001 |
| Hospitalized, ICU | 381 (40.3) | 11.0 | 9.43–12.8 | <.001 |
| CCI, severity weighted, per increase of 1 | 1.05 | 1.03–1.07 | <.001 | |
| 0 | 1337 (4.5) | |||
| ≥1 | 1520 (13.6) | |||
| Vaccination status at time of SARS-CoV-2 infection | ||||
| Unvaccinated | 1654 (6.9) | … | … | |
| 2 mRNA doses | 584 (6.1) | 0.98 | .87–1.09 | .7 |
| >2 mRNA doses | 619 (8.2) | 1.10 | .97–1.24 | .14 |
Multivariable model included only the terms shown. Interaction terms with vaccination status and the main effect of smoking were not included in this model for presentation purposes. PASC was diagnosed between 30 days and 6 months after infection.
Abbreviations: aOR, adjusted odds ratio; CCI, Charlson Comorbidity Index; ICU, intensive care unit; PASC, postacute sequelae of COVID-19.
| Characteristic . | Total With PASC, No. (%) . | aOR . | 95% CI . | P Value . |
|---|---|---|---|---|
| Age, per 10 y | 1.17 | 1.14–1.19 | <.001 | |
| 0–17 | 110 (1.6) | |||
| 18–39 | 730 (5.2) | |||
| 40–64 | 984 (7.4) | |||
| ≥65 | 1033 (15.0) | |||
| Sex | ||||
| Male | 1100 (6.0) | … | … | |
| Female | 1757 (7.7) | 1.51 | 1.38–1.64 | <.001 |
| Race | ||||
| White | 2639 (7.1) | … | … | |
| Asian | 67 (5.4) | 1.07 | .81–1.39 | .6 |
| Black | 99 (6.0) | 1.07 | .85–1.33 | .5 |
| Other | 52 (5.5) | 1.01 | .74–1.36 | >.9 |
| COVID-19 variant era | ||||
| Ancestral | 351 (8.1) | … | … | |
| Alpha | 78 (7.4) | 0.90 | .67–1.18 | .5 |
| Delta | 1179 (7.2) | 0.97 | .84–1.12 | .7 |
| Omicron | 1249 (6.5) | 0.67 | .58–.78 | <.001 |
| Hospitalization for COVID-19 | ||||
| No | 1567 (4.1) | … | … | |
| Hospitalized, no ICU | 909 (37.4) | 10.1 | 9.06–11.2 | <.001 |
| Hospitalized, ICU | 381 (40.3) | 11.0 | 9.43–12.8 | <.001 |
| CCI, severity weighted, per increase of 1 | 1.05 | 1.03–1.07 | <.001 | |
| 0 | 1337 (4.5) | |||
| ≥1 | 1520 (13.6) | |||
| Vaccination status at time of SARS-CoV-2 infection | ||||
| Unvaccinated | 1654 (6.9) | … | … | |
| 2 mRNA doses | 584 (6.1) | 0.98 | .87–1.09 | .7 |
| >2 mRNA doses | 619 (8.2) | 1.10 | .97–1.24 | .14 |
| Characteristic . | Total With PASC, No. (%) . | aOR . | 95% CI . | P Value . |
|---|---|---|---|---|
| Age, per 10 y | 1.17 | 1.14–1.19 | <.001 | |
| 0–17 | 110 (1.6) | |||
| 18–39 | 730 (5.2) | |||
| 40–64 | 984 (7.4) | |||
| ≥65 | 1033 (15.0) | |||
| Sex | ||||
| Male | 1100 (6.0) | … | … | |
| Female | 1757 (7.7) | 1.51 | 1.38–1.64 | <.001 |
| Race | ||||
| White | 2639 (7.1) | … | … | |
| Asian | 67 (5.4) | 1.07 | .81–1.39 | .6 |
| Black | 99 (6.0) | 1.07 | .85–1.33 | .5 |
| Other | 52 (5.5) | 1.01 | .74–1.36 | >.9 |
| COVID-19 variant era | ||||
| Ancestral | 351 (8.1) | … | … | |
| Alpha | 78 (7.4) | 0.90 | .67–1.18 | .5 |
| Delta | 1179 (7.2) | 0.97 | .84–1.12 | .7 |
| Omicron | 1249 (6.5) | 0.67 | .58–.78 | <.001 |
| Hospitalization for COVID-19 | ||||
| No | 1567 (4.1) | … | … | |
| Hospitalized, no ICU | 909 (37.4) | 10.1 | 9.06–11.2 | <.001 |
| Hospitalized, ICU | 381 (40.3) | 11.0 | 9.43–12.8 | <.001 |
| CCI, severity weighted, per increase of 1 | 1.05 | 1.03–1.07 | <.001 | |
| 0 | 1337 (4.5) | |||
| ≥1 | 1520 (13.6) | |||
| Vaccination status at time of SARS-CoV-2 infection | ||||
| Unvaccinated | 1654 (6.9) | … | … | |
| 2 mRNA doses | 584 (6.1) | 0.98 | .87–1.09 | .7 |
| >2 mRNA doses | 619 (8.2) | 1.10 | .97–1.24 | .14 |
Multivariable model included only the terms shown. Interaction terms with vaccination status and the main effect of smoking were not included in this model for presentation purposes. PASC was diagnosed between 30 days and 6 months after infection.
Abbreviations: aOR, adjusted odds ratio; CCI, Charlson Comorbidity Index; ICU, intensive care unit; PASC, postacute sequelae of COVID-19.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
